✦ LIBER ✦

The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

✍ Scribed by Palmer, Andrew J.; Roze, Stéphane; Valentine, William J.; Minshall, Michael E.; Foos, Volker; Lurati, Francesco M.; Lammert, Morten; Spinas, Giatgen A.

Book ID: 121283127
Publisher: Informa plc
Year: 2004
Tongue: English
Weight: 423 KB
Volume: 20
Category: Article
ISSN: 0300-7995
DOI: 10.1185/030079904X1980

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term clinical and economic outcomes

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis

✍ Lee, Won Chan; Samyshkin, Yevgeniy; Langer, Jakob; Palmer, James L. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 279 KB

PDB20 BIPHASIC INSULIN ASPART 30 VERSUS

PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES: LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN

✍ AJ Palmer; M Lammert; WJ Valentine; JA Ray; AS Brandt; S Roze 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PDB26 Projected Long-Term Clinical and E

PDB26 Projected Long-Term Clinical and Economic Outcomes of Exenatide Once Weekly Versus Sitagliptin for the Treatment of Type 2 Diabetes in the UK

✍ Beaudet, A.; Wilson, B.; Caputo, J.; Timlin, L. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PDB50 Long-Term Clinical and Economic Be

PDB50 Long-Term Clinical and Economic Benefit Associated with Liraglutide Versus Sitagliptin Therapy When Added to Metformin in the Treatment of Type 2 Diabetes: a Core Diabetes Model Study

✍ W.C. Lee; Y. Samyshkin; J. Langer; J.L. Palmer 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PDB1 IMPROVED GLYCAEMIC CONTROL AND LESS

PDB1 IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS—RESULTS OF THE DIABETES MELLITUS SIMULATION MODEL

✍ S Maxion-Bergemann; E Müller; R Bergemann; S Walleser; E Huppertz 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

DB1 EVALUATING THE COST-EFFECTIVENESS OF

DB1 EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH OUTCOMES

✍ Chang, J; Sun, F; Li, H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB